Literature DB >> 15064706

Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics.

Elina Levina1, Moshe Oren, Avri Ben-Ze'ev.   

Abstract

beta-Catenin, a structural component of cell-cell adhesions, is also a potent signaling molecule in the Wnt pathway activating target genes together with Lef/Tcf transcription factors. In colorectal and many other types of cancer, beta-catenin is hyperactive owing to mutations in beta-catenin, or in components regulating beta-catenin degradation. Deregulated beta-catenin can cause the activation of p53, a key tumor suppressor mutated in most cancers. Activated p53 can feed back and downregulate beta-catenin. Here we investigated the mechanisms involved in downregulation of beta-catenin by p53. We found that the p53-mediated reduction in beta-catenin involves enhanced phosphorylation of beta-catenin on key NH(2)-terminal serines and requires CK1 and GSK-3beta activities, both being components of the beta-catenin degradation machinery. Mutations in these NH(2)-terminal beta-catenin serines blocked the ability of p53 to enhance the turnover of beta-catenin. p53 also induced a shift in the distribution of the scaffold molecule Axin to a Triton X-100-soluble fraction, and led to depletion of beta-catenin from this Triton-soluble fraction. The majority of Axin and phosphorylated beta-catenin, however, colocalized in Triton X-100-insoluble punctate aggregates near the plasma membrane, and kinetics studies indicated that in the presence of p53 the movement of Axin into and out of the Triton X-100-insoluble fraction is accelerated. These results suggest that p53 induces a faster mobilization of Axin into the degradation complex thereby enhancing beta-catenin turnover as part of a protective mechanism against the development of cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064706     DOI: 10.1038/sj.onc.1207587

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  Activation of p53 by Dishevelled independent of Wnt or planar polarity pathways.

Authors:  Vivianne W Ding; Li-Ping Lin; Andrew L Chiang; Frank McCormick
Journal:  J Mol Med (Berl)       Date:  2007-06-26       Impact factor: 4.599

Review 2.  Signaling and transcriptional regulation in osteoblast commitment and differentiation.

Authors:  Wei Huang; Shuying Yang; Jianzhong Shao; Yi-Ping Li
Journal:  Front Biosci       Date:  2007-05-01

3.  p53 protein regulates Hsp90 ATPase activity and thereby Wnt signaling by modulating Aha1 expression.

Authors:  Sachiyo Okayama; Levy Kopelovich; Gabriel Balmus; Robert S Weiss; Brittney-Shea Herbert; Andrew J Dannenberg; Kotha Subbaramaiah
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

Review 4.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

Review 5.  Crosstalk between Wnt/β-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy.

Authors:  Li Song; Zhuo-Yu Li; Wei-Ping Liu; Mei-Rong Zhao
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

6.  Stable isotope labeling of phosphoproteins for large-scale phosphorylation rate determination.

Authors:  Rosalynn C Molden; Jonathan Goya; Zia Khan; Benjamin A Garcia
Journal:  Mol Cell Proteomics       Date:  2014-02-16       Impact factor: 5.911

Review 7.  Striking the target in Wnt-y conditions: intervening in Wnt signaling during cancer progression.

Authors:  Tura C Camilli; Ashani T Weeraratna
Journal:  Biochem Pharmacol       Date:  2010-03-06       Impact factor: 5.858

8.  Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability.

Authors:  Lin Thorstensen; Guro E Lind; Tone Løvig; Chieu B Diep; Gunn I Meling; Torleiv O Rognum; Ragnhild A Lothe
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

9.  Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.

Authors:  Fu-Ming Zi; Jing-Song He; Yi Li; Cai Wu; Wen-Jun Wu; Yang Yang; Li-Juan Wang; Dong-Hua He; Li Yang; Yi Zhao; Gao-Feng Zheng; Xiao-Yan Han; He Huang; Qing Yi; Zhen Cai
Journal:  Cancer Biol Ther       Date:  2014-07-21       Impact factor: 4.742

10.  Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death.

Authors:  Irene Cappuccio; Agata Calderone; Carla L Busceti; Francesca Biagioni; Fabrizio Pontarelli; Valeria Bruno; Marianna Storto; Georg T Terstappen; Giovanni Gaviraghi; Francesco Fornai; Giuseppe Battaglia; Daniela Melchiorri; R Suzanne Zukin; Suzanne Zukin; Ferdinando Nicoletti; Andrea Caricasole
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.